- Genedrive's PLC (LON: GDR) HepC test just entered the commercial phase as partner Sysmex launched in EMEA and APAC territories in recent weeks
- Re-design of the mTB test in progress, launch date to be announced in the next fiscal year
- Discussions for the disposal of the Services business entered an exclusivity period, expect an update by the end of June
- Careful cash management with a £3.9mln cash balance at the end of February, we would expect a capital raise in the second half of calendar year 2018
As discussed more in depth in our initiation note of November 2017, we value Genedrive PLC on a SOTP basis.
Based on expected revenue of c. £15 mln in 2025, we value Genedrive’s diagnostic division approx. £24 mln.
Including the value we attribute to the Services business and the company's net debt leads to an equity valuation of about £24 mln, 3-4x current market capitalization.Full report is available via Capital Network website